The company presented promising Phase 1 data showing its lead diagnostic candidate successfully detects TDP-43 pathology in ALS patients with appropriate safety and pharmacokinetic profiles. The expansion to Part 2 of the trial and potential to address multiple neurodegenerative diseases represents clinical progress and validates the company's precision medicine approach.
Articles that tag ACIU but are mainly about other companies.
Mentioned as a better-ranked biotech stock with Zacks Rank #2, but no direct connection to the main article content about AbbVie's Juvmo approval.
Zacks Rank #2 (Buy) with narrowing losses (2026 loss estimates improved from 84 cents to 60 cents); consistent earnings beats; however, stock down 16.9% YTD, indicating market skepticism despite operational improvements.
Zacks Rank #2 (Buy) with narrowed loss estimates for 2026, but shares have declined 13.1% year-to-date. Consistent earnings beats suggest operational strength despite stock price weakness.
Carries Zacks Rank #2 (Buy) with narrowed loss estimates, but shares have declined 16% YTD. Consistent earnings beats (33.25% average surprise) provide some positive signal despite negative stock performance.
Zacks Rank #2 (Buy) with improving loss estimates, but negative year-to-date performance of -14.7%. Consistent earnings beats suggest operational strength despite stock underperformance.
Zacks Rank #2 (Buy) with narrowed loss estimates for 2026 (from -$0.84 to -$0.60) and stable 2027 estimates at $0.17. Consistent earnings beats (33.25% average surprise) but stock down 15.3% year-to-date, indicating mixed market sentiment despite operational improvements.
Mentioned as a better-ranked biotech stock (Zacks Rank #2) for comparison purposes only; no direct connection to the main article content.
Zacks Rank #2 (Buy) with narrowing loss estimates for 2026, consistent earnings beats, but negative year-to-date performance of -8.9% indicating mixed market sentiment.
Zacks Rank #2 (Buy) with narrowed loss estimates for 2026 over the past 60 days. Consistent earnings beats in all trailing four quarters with 33.25% average surprise, despite year-to-date decline of 8.9%.
Carries Zacks Rank #2 (Buy) with consistent earnings beats, but shares have declined 9.6% year to date, indicating mixed market sentiment despite positive analyst ratings.
Zacks Rank #2 (Buy) with improving loss estimates for 2026 (narrowed from 84 cents to 60 cents), consistent earnings beats (4 of 4 quarters with 33.25% average surprise), but negative year-to-date performance (-15.9%) indicates mixed market sentiment.
The company secured an amended collaboration with a major pharmaceutical partner (Lilly), received upfront payment of CHF10 million, and demonstrated significant progress with its Morphomer technology platform. The advancement toward IND-enabling studies and potential for over CHF1.7 billion in future milestones indicates strong momentum and validation of their therapeutic approach.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
